News: FDA's Social Media Insight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News: FDA's Social Media Insight


Pharmaceutical Technology Europe
Volume 24, Issue 2

News bites

Vaccines for GAVI

Pfizer and GlaxoSmithKline have entered into separate agreements with the GAVI Alliance to supply pneumococcal vaccines to developing countries. Each company has agreed to supply as many as 480 million doses of their pneumococcal vaccines

Read more at http://www.PharmTech.com/gavivaccines

BMS acquires Inhibitex

In a deal worth almost €2 billion, Bristol-Myers Squibb has commenced a cash tender offer to purchase all outstanding shares of Inhibitex. The transaction will provide BMS with an oral nucleotide polymerase inhibitor that is currently in Phase II development for the treatment of hepatitis C.

Read more at http://www.PharmTech.com/bmsdeal

Sanofi boosts start-up

Sanofi is extending a helping hand to start-up biotech company Warp Drive Bio by providing funding, access to its strains library and expertise in natural products. Two US venture capitalist firms will also invest in the start up, with all three offering funding that could amount during $125 million in the next five years.

Read more at http://www.PharmTech.com/sanofiboost

Ranbaxy's consent decree

Pledging to strengthen procedures and policies to ensure data integrity and comply with cGMP, Ranbaxy has signed a consent decree with the FDA. The company will also make a provision of $500 million to resolve liability in connection with an investigation by the US Department of Justice.

Read more at http://www.PharmTech.com/ranbaxy


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here